Alphatec lowered its full-year 2026 revenue expectation to approximately $862 million, growth of roughly 13%, including surgical revenue of approximately $789 million and EOS revenue of approximately $73 million. The company now expects adjusted EBITDA of approximately $137 million, a 16% margin, and free cash flow of $10 million, citing lower biologics attachment rates and procedure volumes.
ATEC · Alphatec Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 49%
- Last earnings
- Oct 29, 2026
- Latest filing
- 10-Q · Oct 29
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Revenue from products and services increased $24.7 million, or 13%, for the three months ended September 30, 2026, and $75.6 million, or 14%, for the nine months, from higher product volume. Litigation-related expenses decreased $5.9 million, or 91%, mainly due to a litigation settlement in the prior-year nine months. Cash and cash equivalents were $79.9 million at September 30, 2026, down from $160.8 million at December 31, 2025.
Alphatec Holdings, Inc. reported $221 million revenue for September 30, 2026, up 13% year-over-year, and $38 million adjusted EBITDA. For fiscal year 2026, it expects approximately $862 million revenue and approximately $137 million adjusted EBITDA.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. ATEC delivered Q2 revenue of $214M (up 15%) with surgical revenue up 17% on 20% case volume growth, raised full-year adjusted EBITDA guidance to ~$140M from ~$134M, while reaffirming revenue (~$882M) and free cash flow (≥$20M) outlook; revenue per case guidance moved from flattish to down low single digits as biologics attach rate only stabilized.
- + Q2 surgical revenue grew 17% to $196M on 20% case volume growth and 24% net new surgeon user growth.
- + Raised full-year 2026 adjusted EBITDA guidance to ~$140M from prior ~$134M.
- + Gross margin expanded 260 bps year-over-year to 72.5%, with operating expenses improving ~260 bps as a percentage of revenue.
- + Refinancing extends maturities to 2031 and is expected to reduce annual interest expense by more than $6M.
- + EOS Insight adoption driving ~32% implant revenue lift per surgeon within six months of Go-Live.
- − Full-year revenue per case guidance lowered from flattish to down low single digits as biologics attach only stabilized rather than improved.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $56.69M | six months ended June 30, 2026 | — |
| Adjusted EBITDA margin non-GAAP | 14% | six months ended June 30, 2026 | — |
| Adjusted EBITDA margin expansion non-GAAP | 420 | the second quarter | — |
| Case volume growth | 20% | the second quarter | — |
| Net new surgeon users growth | 24% | the second quarter | — |
| Non-GAAP gross margin non-GAAP | 72.5% | Quarter Ended June 30, 2026 | — |
| Non-GAAP gross profit non-GAAP | $154.72M | three months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Gross profit, GAAP 154.1M
+65K amortization of acquired intangible assets
+559K stock-based compensation
= Non-GAAP gross profit 154.72M
|
|||
| Non-GAAP net income non-GAAP | $11.73M | six months ended June 30, 2026 | — |
| Non-GAAP net income per share non-GAAP | $0.07 | three months ended June 30, 2026 | — |
| Non-GAAP operating expenses non-GAAP | $135M | Quarter Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Operating expenses, GAAP 156.01M
-17.59M Stock-based compensation
+86K Litigation-related expenses
-3.92M Amortization of acquired intangible assets
+0K Restructuring expenses
= Non-GAAP operating expenses 134.59M
|
|||
| Surgical revenue | $196M | Quarter Ended June 30, 2026 | — |
| Surgical revenue growth | 17% | the second quarter | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATEC
this stock
Alphatec Holdings, Inc.
|
$1.04B | -68.3% | -15.4% | — | 9.2% |
|
ABT
Abbott Laboratories
|
$178.39B | -17.8% | +5.7% | 38.4 | 1.1% |
|
MDT
Medtronic plc
|
$127.84B | +4.0% | +8.4% | 24.6 | 1.8% |
|
SYK
Stryker Corp
|
$118.01B | -11.8% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$60.85B | -56.0% | +12.5% | 17.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 29, 2026
- This year
- 17
Revenue from products and services increased $24.7 million, or 13%, for the three months ended September 30, 2026, and $75.6 million, or 14%, for the nine months, from higher product volume. Litigation-related expenses decreased $5.9 million, or 91%, mainly due to a litigation settlement in the prior-year nine months. Cash and cash equivalents were $79.9 million at September 30, 2026, down from $160.8 million at December 31, 2025.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATEC | -5.5% | -39.9% | -10.7% | -5.1% | -68.3% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +3.0% | -30.6% | -1.5% | +3.6% | -69.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.